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Editor’s Note: Letters to the Editor contribute new scien-
tific data, comment on a recent article in TRANSFUSION,
or provide an opinion on an important topic. Letters ex-
pressing opinions are usually based on an analysis citing
specific published studies. We are publishing the following
letter, submitted by authors from 26 institutions, as an ex-






WBC reduction represents an advance in the technology of
blood component preparation. For selected patients, the
prevention of several transfusion complications resulting
from recipients’ exposure to allogeneic donor WBCs has
been adequately documented by clinical trials. However,
extending the use of WBC-reduced blood components to all
patients should be justified on the basis of published data
documenting significant benefit, regardless of diagnoses or
reasons for transfusion. The signatories of this letter have
reviewed the available data, including those presented in
great detail in recent publications.1, 2 It is our view that pub-
lished reports fail to document a substantial health benefit
that would serve to justify WBC reduction of cellular com-
ponents transfused to all patients. Accordingly, we feel that
the currently available evidence regarding the deleterious
effects of allogeneic blood transfusion is not sufficiently
compelling to warrant universal WBC reduction for the pre-
vention of these effects.
Although the lack of documentation of significant ben-
efit for all patients is foremost in our minds, no rational con-
sideration of a policy of universal WBC reduction can ignore
cost considerations. The cost in the United States has been
estimated to be more than $600 million per year.1 We decry
the forced expenditure of such an enormous amount of
money without commensurate patient benefits.
Thus, we strongly oppose measures that would com-
pel us to supply only WBC-reduced blood components for
all of our patients. We will continue to strive to maintain a
policy of selective WBC reduction until data are forthcom-
ing from well-designed scientific studies that justify a
change in policy. In the meantime, we urge regulatory agen-
cies and blood centers to withhold the forced implemen-
tation of universal WBC reduction.
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